Pharmaceutical companies are scrambling to make last-minute announcements ahead of a Trump administration deadline on Monday for the firms to lower U.S. drug prices. But it’s not clear if the initiatives — which include investments in the U.S. and new direct-to-consumer models — will meet the president’s expectations

President Trump in July sent letters to 17 major pharma companies, demanding that they take several actions to lower U.S. drug prices in line with what other countries pay as part of his so-called “most-favored nations” policy.

So far, companies have expressed the greatest enthusiasm for one of the demands in the letters, in particular — that they implement direct-to-consumer models for their drugs, with AstraZenca and Bristol Myers Squibb this week both announcing new

See Full Page